Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Gut|December 24, 2014
Randomised controlled trial of mesalazine in IBSGiovanni Barbara, Cesare Cremon, Vito Annese, et al.
Alimentary Pharmacology & Therapeutics|July 25, 2022
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Federica Crispino, et al.
Frontiers in Medicine|April 28, 2023
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel diseaseMarco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2017
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)Livia Biancone, Vito Annese, Sandro Ardizzone, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 20, 2021
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in ItalyAlessandro Vitello, Mauro Grova, Daniela Pugliese, et al.
Cancers|February 15, 2022
Incident Colorectal Cancer in Inflammatory Bowel DiseaseBenedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|September 10, 2019
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Pageof 5